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were investigated via chart review, with adjudication by 
hepatologists.
Results In Altos and VA, respectively, the total RCC 
patients were: pazopanib (156, 243), bevacizumab 
(122, 99), sorafenib (82, 249) and sunitinib (285, 751). 
PHARMO contained too few patients to be included. Few 
cases of alanine aminotransferase (ALT) ≥8× the upper 
limit of normal were seen across the anti-VEGF cohorts; 
incidence rates (per 100 person-years) ranged from 0 (suni-
tinib) to 8.2 (pazopanib) in Altos and from 0 (bevacizumab 
and sorafenib) to 2.1 (pazopanib) among VA patients. No 
cases of Hy’s law identified by combination LC eleva-
tions were seen in patients treated with pazopanib or bev-
acizumab; one case was observed in those treated with 
sorafenib, and two cases were found among sunitinib users. 
One case of adjudicated DILI was observed in a sunitinib-
treated patient; none were found among patients treated 
with pazopanib, bevacizumab or sorafenib.
Conclusions Severe liver injury occurred infrequently dur-
ing exposure to pazopanib and other anti-VEGF therapies 
in a population-based setting.
Keywords Hepatotoxicity · Liver chemistry · Renal cell 
carcinoma · Pazopanib · Anti-VEGF
Introduction
Pazopanib is a tyrosine kinase inhibitor indicated for the 
treatment of advanced renal cell carcinoma (RCC) and 
advanced soft tissue sarcoma. Prior to US Food and Drug 
Administration (FDA) approval of pazopanib for RCC in 
2009, hepatotoxicity was observed in clinical trials, includ-
ing two fatalities [1]. This led to a black box warning in the 
product label regarding liver safety and monitoring [2].
Abstract 
Purpose To quantify the hepatic safety of pazopanib and 
comparator anti-vascular endothelial growth factor (VEGF) 
therapies in clinical practice among renal cell carcinoma 
(RCC) patients.
Methods A population-based cohort study of new anti-
VEGF users was conducted in two US healthcare data-
bases, Department of Veterans Affairs (VA) and an oncol-
ogy practice network (Altos), and the PHARMO Database 
Network in The Netherlands. A common protocol was 
used to collect liver chemistry (LC) data from anti-VEGF 
initiation through 4 years of follow-up. In the VA popula-
tion, suspected drug-induced liver injury (DILI) outcomes 
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Pazopanib works in part by targeting tyrosine kinase 
inhibitors (TKIs) of vascular endothelial growth factor 
(VEGF) receptors. Other related medications indicated 
for RCC include the TKIs sunitinib and sorafenib as well 
as bevacizumab, an anti-VEGF monoclonal antibody [3]. 
Elevations in liver chemistry (LC) tests including alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), and bilirubin have been found 
not only with pazopanib [1, 4, 5], but also in some studies 
with bevacizumab [6, 7], sunitinib [4, 8] and sorafenib [4, 
9]. Similar to pazopanib, a boxed warning regarding hepa-
totoxicity exists for sunitinib [10]. As part of post-approval 
regulatory commitments for pazopanib, a post-marketing 
safety study was conducted in three electronic medical 
record (EMR) databases to examine the incidence of hepa-
totoxicity in RCC patients treated with pazopanib or com-
parator anti-VEGF drugs.
Materials and methods
This population-based retrospective cohort study used 
a distributed data network that included data from three 
EMR databases: Altos, the US Department of Veterans 
Affairs Veterans Health Administration System (VA), and 
PHARMO Database Network. Altos contains EMR data 
for over 400,000 cancer patients seen in 150 outpatient 
oncology practices serving more than 1000 clinicians in 
the USA. Data obtained for each patient visit include diag-
noses and treatment prescribed by or administered in the 
oncology clinic. Laboratory results are available through 
an automated link from the clinical laboratory. The VA is 
a national, integrated healthcare system with longitudi-
nal clinical data for more than 12 million veterans during 
the most complete era of electronic data capture. Data on 
inpatient and outpatient encounters, procedures, all inpa-
tient and outpatient medications, and all laboratory tests 
are available spanning 13 years. In addition, data on cause-
specific mortality are available for all veterans. The Dutch-
based PHARMO Institute has access to the PHARMO 
Database Network serving more than three million resi-
dents in The Netherlands. The database includes informa-
tion on patient demographics, drug dispensing, hospital 
morbidity, clinical laboratory, pathology and general prac-
titioner information.
Across the three databases, a common protocol was 
implemented by a coordinating center to ensure that patient 
selection and methodology were consistent within each 
database. New adult (18+ years) users of pazopanib, beva-
cizumab, sorafenib, or sunitinib with a diagnosis of RCC 
(ICD-9 codes 189.0 or 189.1) were identified from the 
earliest date of availability of pazopanib in the each health 
system (October 1, 2009, in the USA; February 1, 2011, 
in The Netherlands) through February 17, 2013 (6 weeks 
prior to the study end date of March 31, 2013). Because 
many patients beginning cancer treatment may be new to 
the oncology practice, no minimum duration of enroll-
ment in the healthcare database was required prior to the 
drug start date. Included patients had at least one ALT and 
bilirubin measurement within 30 days before or on the drug 
start date to allow a comparison between drug initiation 
(baseline) and follow-up laboratory values. Patients pre-
scribed more than one anti-VEGF agent concurrently were 
excluded, but patients could use more than one anti-VEGF 
agent during different time periods. Use of other antineo-
plastic treatments was permitted.
Exposure to anti‑VEGF drugs
Dates of exposure to the oral medications were derived 
from prescription records; when duration of treatment 
was not specified, a 30-day duration was assigned for 
pazopanib and sorafenib and 28 days for sunitinib. Beva-
cizumab was recorded as clinic administrations, with each 
administration assigned a duration of 14 days (i.e., the 
indicated interval between infusions). A continuous course 
of treatment was defined as sequential prescriptions for the 
index drug, including all refills indicated in the prescrip-
tion, separated by gaps of no more than 30 days. A gap 
of greater than this duration flagged the end of one course 
of therapy and the start of a new treatment episode. Ini-
tiation of an alternate treatment for RCC that would not 
be expected to be used in combination with the index 
drug (including all of the other anti-VEGF drugs), with no 
repeat prescription of the initial drug after the start of the 
new treatment, was also used as an indicator of the end of 
a treatment episode.
Baseline variables
Baseline is defined as the date of the anti-VEGF drug ini-
tiation (drug start date). The following baseline patient 
demographic, medical, and treatment characteristics were 
identified, as available in the various databases: age on the 
drug start date, gender, concomitant medications (defined 
as drugs ordered or administered within 30 days prior to 
the drug start date or during any period of anti-VEGF drug 
exposure), chemotherapy agents received prior to the drug 
start date, line of treatment of the qualifying regimen given 
on the drug start date (defined from all available informa-
tion on chemotherapy exposure that preceded the regimen 
received on the drug start date) and presence and type of 
secondary tumors (identified using ICD-9 codes 196.
xx–198.xx).
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Outcomes
The following LC elevation thresholds in relation to the 
upper limit of normal (ULN) were studied in all patients 
during the first exposure window to each anti-VEGF 
drug: ALT or AST (≥3x–4.99x, ≥5x–9.99x, ≥2x, ≥3x, 
≥5x, ≥8x and ≥10x), ALP (>1x, >2x, >3x, ≥2x to 2.99x, 
≥3x–4.99x and ≥5x), and total serum bilirubin (>1x, 
≥1.5x–1.99x, ≥2x–4.99x, ≥2x and ≥5x). The combina-
tion of LC elevations indicative of possible Hy’s law was 
defined as ALT or AST ≥3x ULN, total bilirubin ≥2x ULN 
and ALP <2x ULN [11, 12].
Within the VA population only, drug-induced liver 
injury (DILI) events were also investigated. Patients were 
screened from the earliest to latest exposure date of any 
of the four anti-VEGF drugs, plus an additional 90 days 
past the last exposure date, for the occurrence of ALT >3x 
ULN concurrently with bilirubin >2x ULN, or for ICD-9 
codes indicating potential DILI events (277.4, 570.x, 572.8, 
573.3, 573.8, 576.8 or 782.4). An abstraction form was 
completed from the national EMR data for each patient 
who screened positive on either of these indicators; the 
specific anti-VEGF drugs received were blinded on the 
completed abstraction forms. Three members of a panel 
comprised by VA hepatologists and gastroenterologists 
independently reviewed each abstraction form and com-
pleted a case review form with a judgment on whether or 
not each case represented a DILI event. Following these 
independent reviews, cases were discussed and discrep-
ancies resolved via teleconferences. Any disagreement 
that was not resolved through discussion was decided by 
majority vote. Case adjudication forms were then com-
pleted to reflect the final decision. An incident DILI event 
was deemed to have occurred if the expert panel agreed 
that there was at least a 50 % likelihood that the anti-VEGF 
drug contributed to a liver injury outcome.
Statistical analysis
All analyses were run separately within each of the contrib-
uting databases. Data were analyzed at 6-month intervals 
during the first 4 years following FDA approval of pazo-
panib for treatment of RCC. At each interval, all cumula-
tively accrued patients were incorporated into the analyses; 
the present paper reports the findings from the final patient 
cohorts.
The baseline characteristics were summarized as num-
ber and percentage of patients for categorical variables 
or mean and standard deviation (SD) for continuous vari-
ables. Analysis of each category of LC elevation included 
only patients with no prior elevation at or above the lower 
threshold for the given elevation. For example, a patient 
with a baseline ALT of 3x ULN was ineligible for the anal-
yses of ALT ≥3x ULN to 4.99x ULN, ≥2x ULN and ≥3x 
ULN, but was eligible for the other categories of ALT ele-
vation. Cumulative incidence was calculated as the number 
of patients with an LC result in the given range divided by 
the number of patients evaluated. A one-sided, 97.5 % CI 
was estimated for cumulative incidence when the number 
of cases was zero. The incidence rate of each LC elevation 
was calculated as the number of patients with an elevation 
divided by the total amount of person-time. Total duration 
Table 1  Baseline characteristics of pazopanib and other anti-VEGF initiators among renal cell carcinoma patients in the Altos and Veterans 
Affairs (VA) databases
Patient characteristic, n (%) Pazopanib Bevacizumab Sorafenib Sunitinib
Altos VA Altos VA Altos VA Altos VA
N = 156 N = 243 N = 122 N = 99 N = 82 N = 249 N = 285 N = 751
Age, mean (SD) 65.7 (9.9) 67.5 (9.0) 63.5 (11.8) 67.3 (8.7) 66.5 (9.9) 66.8 (8.9) 67.0 (10.6) 67.1 (8.6)
Male gender 107 (68.6 %) 239 (98.4 %) 81 (66.4 %) 99 (100 %) 58 (70.7 %) 245 (98.4 %) 197 (69.1 %) 741 (98.7 %)
Metastases
 Lung 31 (19.9 %) 122 (50.2 %) 14 (11.5 %) 37 (37.4 %) 12 (15.6 %) 115 (46.2 %) 37 (13.0 %) 351 (46.7 %)
 Liver 6 (3.8 %) 46 (18.9 %) 5 (4.1 %) 24 (24.2 %) 2 (2.4 %) 44 (17.7 %) 10 (3.5 %) 108 (14.4 %)
 Bone or marrow 39 (25.0 %) 90 (37.0 %) 34 (27.9 %) 27 (27.3 %) 15 (18.3 %) 75 (30.1 %) 57 (20.0 %) 241 (32.1 %)
 Brain or spinal cord 3 (1.9 %) 29 (11.9 %) 6 (4.9 %) 16 (16.2 %) 3 (3.7 %) 29 (11.7 %) 9 (3.2 %) 87 (11.6 %)
 Adrenal gland 8 (5.1) 30 (12.4 %) 2 (1.6 %) 7 (7.1 %) 3 (3.7 %) 23 (9.2 %) 6 (2.1 %) 61 (8.1 %)
 None n/a 3 (1 %) n/a 3 (3 %) n/a 5 (2 %) n/a 21 (2.8 %)
Line of treatment
 First line 60 (38.5 %) 174 (71.6 %) 37 (30.3 %) 59 (59.6 %) 26 (31.7 %) 186 (74.7 %) 233 (81.8 %) 558 (74.1 %)
 Second line 40 (25.6 %) 50 (20.6 %) 43 (35.2 %) 20 (20.2 %) 28 (34.1 %) 51 (20.5) 40 (14.0 %) 69 (9.2 %)
 Third line or higher 56 (35.9 %) 19 (7.8 %) 42 (34.4 %) 20 (20.2 %) 28 (34.2 %) 12 (4.8 %) 12 (4.2 %) 16 (2.1 %)
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Table 2  Incidence rate (IR) per 100 person-years and cumulative incidence (%) of liver chemistry (LC) elevations among renal cell carcinoma 
patients in the Altos and Veterans Affairs (VA) populations
Persons with baseline elevations that exceeded a specified threshold were excluded from incidence analysis (hence, varying denominators). Pos-
sible Hy’s law: the combination of LC elevations indicative of possible Hy’s law was defined as ALT or AST ≥3x ULN, total bilirubin ≥2x 
ULN and ALP <2x ULN
A one-sided, 97.5 % CI was estimated for cumulative incidence when the number of cases was zero
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, Cum Inc cumulative inci-
dence, SD standard deviation, ULN upper limit of normal
LC test and 
threshold
Pazopanib Bevacizumab Sorafenib Sunitinib
Altos VA Altos VA Altos VA Altos VA
ALT ≥2x ULN
 N cases/total 9/147 34/198 11/115 6/83 4/74 12/194 25/269 42/570
















 Cum. Inc. (%) 
(95 % CI)
6.1 (2.8, 11.3) 17.2 (12.2, 
23.2)
9.6 (4.9, 16.5) 7.2 (2.7, 
15.1)
5.4 (1.5, 13.3) 6.2 (3.2, 10.6) 9.3 (6.1, 13.4) 7.4 (5.4, 9.8)
ALT ≥3x ULN
 N cases/total 7/151 23/201 7/119 3/86 3/75 6/198 8/273 18/584






7.7 (6.2, 9.5) 16.7 (13.1, 
20.9)
7.2 (6.3, 8.3) 11.5 (10.2, 
13.0)
6.5 (6.0, 7.1)
 Cum. Inc. (%) 
(95 % CI)
4.6 (1.9, 9.3) 11.4 (7.4, 
16.7)
5.9 (2.4, 11.7) 3.5 (0.7, 9.9) 4 (0.8, 11.3) 3.0 (1.1, 6.5) 2.9 (1.3, 5.7) 3.1 (1.8, 4.8)
ALT ≥8x ULN
 N cases/total 3/155 2/204 2/122 0/86 1/77 0/200 0/279 4/587
 IR (95 % CI) 8.2 (6.9, 9.6) 2.1 (1.8, 2.4) 4.8 (4.0, 5.8) 0 (0, 11.1) 5.4 (4.3, 6.8) 0 (0, 5.2) 0 (0, 6.0) 1.4 (1.3, 1.5)
 Cum. Inc. (%) 
(95 % CI)
1.9 (0.4, 5.6) 1.0 (0.1, 3.5) 1.6 (0.2, 5.8) 0 (0, 5.0) 1.3 (0.0, 7.0) 0 (0, 2.2) 0 (0, 1.6) 0.7 (0.2, 1.7)
Bilirubin >1x ULN
 N cases/total 14/152 31/198 8/117 18/86 6/79 27/190 23/268 104/579
















 Cum. Inc. (%) 
(95 % CI)
9.2 (5.1, 15.0) 15.7 (10.9, 
21.5)
6.8 (3, 13.0) 20.9 (12.9, 
31.1)
7.6 (2.8, 15.8) 14.2 (9.6, 20) 8.6 (5.5, 12.6) 18.1 (15, 
21.4)
Bilirubin ≥1.5x ULN to 1.99x ULN
 N cases/total 3/155 11/203 2/119 3/88 2/81 11/202 6/277 31/590
 IR (95 % CI) 8.1 (6.9, 9.5) 12.0 (10.4, 
13.8)




8.4 (7.4, 9.4) 11.1 (10.3, 
12.1)
 Cum. Inc. (%) 
(95 % CI)
1.9 (0.4, 5.6) 5.4 (2.7, 9.5) 1.7 (0.2, 5.9) 3.4 (0.7, 9.6) 2.5 (0.3, 8.6) 5.4 (2.8, 9.5) 2.2 (0.8, 4.7) 5.3 (3.6, 7.4)
Bilirubin ≥2.0x ULN
 N cases/total 3/155 6/203 1/120 2/88 1/81 10/202 3/282 30/593
 IR (95 % CI) 8.1 (6.8, 9.4) 6.5 (5.6, 7.5) 2.6 (2.1, 3.1) 4.9 (3.9, 6.0) 5.3 (4.2, 6.5) 11.9 (10.4, 
13.7)
4.1 (3.6, 4.6) 10.5 (9.7, 
11.4)
 Cum. Inc. (%) 
(95 % CI)
1.9 (0.4, 5.6) 3.0 (1.1, 6.3) 0.8 (0.0, 4.6) 2.3 (0.3, 8.0) 1.2 (0.0, 6.7) 5.0 (2.4, 8.9) 1.1 (0.2, 3.1) 5.1 (3.4, 7.1)
Possible Hy’s law
 N cases/total 0/155 0/187 0/122 0/83 0/81 1/182 0/282 2/543
 IR (95 % CI) 0 (0, 11.7) 0 (0, 9.6) 0 (0, 10.5) 0 (0, 17.1) 0 (0, 23.1) 1.3 (11.4, 
15.2)
0 (0.6) 0.8 (4.2, 6.0)
 Cum. Inc. (%) 
(95 % CI)
0 (0, 2.8) 0 (0, 4.1) 0 (0, 3.5) 0 (0, 6.7) 0 (0, 5.3) 0.6 (0.0, 3.0) 0 (0, 1.5) 0.4 (0.0, 1.3)
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of follow-up was obtained by summing the total anti-VEGF 
drug exposure time across multiple separate periods of 
exposure for patients with gaps in treatment. Person-time 
was censored at the time of the first LC elevation for all 
incidence rates.
In addition to the overall analyses, two sets of strati-
fied analyses were performed. First, the statistics described 
above were stratified by line of therapy on the drug start 
date; patients with the anti-VEGF drug as their first line of 
therapy were analyzed separately from those who received 
the drug as their second or higher line of therapy. Second, 
the time to event for patients with ALT ≥3x ULN, total bil-
irubin ≥2x ULN and for the Hy’s law combination were 
summarized. Ethical approvals/subject consent for the pro-
tection of human subjects via institutional review board 
or other ethical board review was obtained at the VA and 
PHARMO. Data obtained from the Altos database were 
deidentified and HIPPA compliant; thus, ethics approval 
was not needed.
Results
A total of 156 pazopanib initiators in the Altos database 
and 243 in the VA qualified for the analysis. Pazopanib pre-
scription in the PHARMO Database Network lagged con-
siderably behind the US-based data sources, due in part to 
later reimbursement, formulary approval and availability 
of the drug in The Netherlands (February 2011), with only 
three pazopanib initiators identified by the end of the study 
period. This database was therefore excluded from the pre-
sent analyses. Pazopanib was used for a mean duration of 
4.2 months in Altos and 10.3 months in the VA population. 
The mean age was 65.1 years for Altos and 68.1 for the VA 
cohort; 64.2 and 98.3 % of patients were male in Altos and 
the VA, respectively (Table 1). Pazopanib was prescribed as 
first-line therapy for 38.5 % of Altos patients and 71.6 % of 
patients in the VA.
Overall, the number of patients with ALT ≥3x ULN 
ranged from 3 to 23 across the anti-VEGF cohorts, cor-
responding to an incidence rate of 6.5–25.9 per 100 per-
son-years (py); the highest rates were observed among 
pazopanib-treated patients from the VA (Table 2). Few 
cases (range 0–4) of ALT ≥8x ULN were seen across the 
anti-VEGF cohorts, resulting in an incidence rate of 0–8.2 
per 100 py. Rates of bilirubin elevation ≥2x ULN ranged 
from 2.6 to 11.9 per 100 py (range 1–30 cases), with the 
highest rates found among the patients from the VA treated 
with sorafenib or sunitinib. The median time to onset of 
these liver events varied substantially across the anti-VEGF 
cohorts (Table 3).
 There was no discernible pattern in the variation of 
incidences for the first-line setting (Table 4) compared to 
the second-line setting (Table 5), aside from a drop in the 
incidence rate for most measures of ALT or bilirubin eleva-
tion among the pazopanib-treated cohort in both the Altos 
and VA databases. The exception was a greater incidence 
rate (per 100 py) of bilirubin ≥2x ULN in the second-line 
setting compared to the first-line setting, respectively, for 
pazopanib users in Altos (9.3, 6.3) and the VA (8.1, 5.4). 
No cases of Hy’s law identified by combination LC ele-
vations were seen in patients treated with pazopanib or bev-
acizumab; three cases were observed in those treated with 
sorafenib (n = 1) and sunitinib (n = 2) at the VA. Among 
Table 3  Time to select liver chemistry (LC) elevation events in Altos and Veteran Affairs databases
Possible Hy’s law: the combination of LC elevations indicative of possible Hy’s law was defined as ALT or AST ≥3x ULN, total bilirubin ≥2x 
ULN and ALP <2x ULN
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal
Drug LC elevation Altos Veteran Affairs
No. events Mean (median) days to event No. events Mean (median) days to event
Pazopanib ALT ≥3x ULN 7 82.7 (61) 23 149 (56)
Total bilirubin ≥2x ULN 3 73.3 (38) 6 311 (382)
Possible Hy’s law 0 NA 0 NA
Bevacizumab ALT ≥3x ULN 7 84.4 (84) 3 236 (218)
Total bilirubin ≥2x ULN 1 112 (112) 2 97 (97)
Possible Hy’s law 0 NA 0 NA
Sorafenib ALT ≥3x ULN 3 57 (60) 6 160 (89)
Total bilirubin ≥2x ULN 1 28 (28) 10 135 (57)
Possible Hy’s law 0 NA 1 162 (162)
Sunitinib ALT ≥3x ULN 8 79.1 (82.5) 18 96 (41)
Total bilirubin ≥2x ULN 3 60.7 (77) 30 71 (41)
Possible Hy’s law 0 NA 2 31 (31)
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the VA population, one case of adjudicated DILI, as cap-
tured by ICD-9 codes, was found in a sunitinib-treated 
patient. No adjudicated case of DILI was seen among 
patients treated with pazopanib, bevacizumab or sorafenib.
Discussion
Results from this study show that severe liver injury 
occurred infrequently during pazopanib exposure in a popu-
lation-based, real-world setting. Further, no combinations of 
LC elevations meeting the laboratory definition of Hy’s law 
were observed in all pazopanib-exposed patients from either 
database, and no pazopanib-related adjudicated DILI out-
comes were identified among more than 300 RCC patients 
accrued in the VA. Few liver toxicity events were identified 
among patients using the other anti-VEGF agents.
Liver toxicity among pazopanib users was less fre-
quently reported in the present population-based study 
compared to a recent report of 1149 pazopanib-treated 
RCC patients from nine prospective clinical trials [1]. 
Among the trial participants, 23 % of patients developed 
elevated ALT >3x ULN compared to 4.6 % of patients 
in the Altos population and 11.4 % among VA patients 
for ALT ≥3x ULN. Further, the cumulative incidence of 
severe liver toxic was higher among clinical trial patients 
(ALT >8x ULN, 8.4 %) compared to the Altos (1.9 %) 
and VA (1.0 %) population (ALT ≥8x ULN). It is pos-
sible that transient or asymptomatic LC elevations were 
missed in the present study of real-world patients where 
Table 4  Incidence rate (IR) per 100 person-years of liver chemistry (LC) elevation among renal cell carcinoma with selected treatment as first 
line of therapy, Altos and Veterans Affairs (VA)
Possible Hy’s law: the combination of LC elevations indicative of possible Hy’s law was defined as ALT or AST ≥3x ULN, total bilirubin ≥2x 
ULN and ALP <2x ULN
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, SD standard deviation, ULN 
upper limit of normal
LC test and 
threshold
Pazopanib Bevacizumab Sorafenib Sunitinib
Altos VA Altos VA Altos VA Altos VA
ALT ≥2x ULN
 N cases/total 3/57 24/123 2/35 2/48 1/24 12/136 24/221 37/500

















 N cases/total 4/59 20/125 2/36 2/49 1/24 6/139 7/224 16/513








8.6 (6.4, 11.4) 13.3 (8.5, 
19.8)




 N cases/total 2/60 2/127 1/37 0/49 0/24 0/140 0/230 4/516




3.4 (2.9, 4.1) 6.6 (4.7, 9.1) 0 (0, 18.7) 0 (0, 57.3) 0 (0, 6.6) 0 (0, 7.0) 1.6 (1.4, 1.7)
Bilirubin >1x ULN
 N cases/total 8/59 20/122 2/37 12/51 2/25 21/132 17/219 97/508


















Bilirubin ≥1.5x ULN to 1.99x ULN
 N cases/total 2/60 8/126 1/37 2/51 0/26 10/142 5/226 29/520






6.6 (4.7, 9.1) 8.1 (6, 10.6) 0 (0, 55.8) 15.3 (12.9, 
18.1)
8.3 (7.2, 9.4) 11.4 (10.4, 
12.4)
Bilirubin ≥2x ULN
 N cases/total 1/60 3/126 1/37 1/51 0/26 9/142 3/231 26/523
 IR (95 % 
CI)
6.3 (4.8, 8.1) 5.4 (4.5, 6.5) 6.6 (4.6, 9.1) 4.0 (3.0, 5.2) 0 (0, 55.8) 13.7 (11.5, 
16.1)
4.8 (4.2, 5.5) 10.0 (9.1, 10.8)
Possible Hy’s law
 N cases/total 0/60 0/115 0/37 0/47 0/25 1/126 0/231 2/477
 IR (95 % 
CI)
0 (0, 27.1) 0 (0, 24.9) 0 (0, 28.6) 0 (0, 24.9) 0 (0, 56.3) 1.6 (1.4, 1.9) 0 (0, 7.0) 0.8 (4.5, 6.7)
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liver monitoring may be less rigorous compared to a trial 
setting.
Several factors are potential limitations in this study. Small 
numbers of patients in several analytic groups, including 
line of therapy, led to some imprecise estimates. Advanced 
RCC could not be identified separately from total kidney 
cancers; metastases may be underreported, especially in the 
Altos database. Exposure time to oral medications, includ-
ing pazopanib, imputed from dates for orders and refills may 
be imprecise, resulting in inaccurate computation of person-
time used in the incidence rate calculations. It is also possible 
that some pazopanib users were not new users on the drug 
start date, if prior pazopanib prescriptions did not appear in 
the database, leading to an underestimate for the rate of LC 
elevations during treatment. In the Altos population, serious 
liver events resulting in hospitalization and LC elevations 
measured outside the oncology practice EMR could not be 
captured, unless the information was manually entered into 
the EMR database, thus potentially underestimating the rate 
of severe LC elevations. The VA database included hospital 
data and can therefore allow for fuller capture of patient expe-
riences, although patients who received medical care outside 
of the VA system may also have had missing LC test results. 
It is possible the ICD-9 codes used for screening potential 
cases of DILI in the VA population may be inaccurate.
This population-based study has a number of strengths. 
Patients come from real-world oncology settings, allowing 
for more generalizable results compared to clinical trial pop-
ulations. The EMR contains data from usual clinical prac-
tice, with issues such as dosing and adherence uninfluenced 
Table 5  Incidence rate (IR) per 100 person-years of liver chemistry (LC) elevation among renal cell carcinoma with selected treatment as sec-
ond line of therapy or higher, Altos and Veterans Affairs (VA)
Possible Hy’s law: the combination of LC elevations indicative of possible Hy’s law was defined as ALT or AST ≥3x ULN, total bilirubin ≥2x 
ULN and ALP <2x ULN
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, SD standard deviation, ULN 
upper limit of normal
LC test and 
threshold
Pazopanib Bevacizumab Sorafenib Sunitinib
Altos VA Altos VA Altos VA Altos VA
ALT ≥2x ULN
 N cases/total 6/90 10/75 9/80 4/35 3/50 0/58 1/48 5/70












0 (0, 24.2) 9.5 (7.0, 12.6) 22.4 (17.5, 
28.3)
ALT ≥3x ULN
 N cases/total 3/92 3/76 5/83 1/37 2/51 0/59 1/49 2/71




7.9 (6.2, 9.9) 19.4 (15.4, 
24.0)
6.3 (4.5, 8.7) 19.0 (14.2, 
25.0)
0 (0, 24.2) 9.4 (6.9, 12.4) 8.1 (6.3, 10.2)
ALT ≥8x ULN
 N cases/total 1/95 0/77 1/85 0/37 1/53 0/60 0/49 0/71
 IR (95 % 
CI)
4.7 (3.8, 5.7) 0 (0, 11.4) 3.8 (3.0, 4.7) 0 (0, 27.5) 9.2 (6.9, 12.1) 0 (0, 23.8) 0 (0, 41.1) 0 (0, 17.3)
Bilirubin >1x ULN
 N cases/total 6/93 11/76 6/80 6/35 4/54 6/58 6/49 7/68


















Bilirubin ≥1.5x ULN to 1.99x ULN
 N cases/total 1/95 3/77 1/82 1/37 2/55 1/60 1/51 2/70
 IR (95 % 
CI)
4.7 (3.8, 5.8) 8.0 (6.3, 10.0) 4.2 (3.4, 5.3) 6.3 (4.4, 8.7) 18.0 (13.5, 
23.3)
5.5 (4.2, 7.1) 8.7 (6.5, 11.5) 8.4 (6.6, 10.7)
Bilirubin ≥2x ULN
 N cases/total 2/95 3/77 0/83 1/37 1/55 1/60 0/51 4/70
 IR (95 % 
CI)
9.3 (7.6, 11.4) 8.1 (6.4, 10.2) 0 (0, 18.3) 6.3 (4.4, 8.7) 9.0 (6.8, 11.7) 5.6 (4.3, 7.2) 0 (0, 38.3) 17.0 (13.2, 
21.4)
Possible Hy’s law
 N cases/total 0/95 0/72 0/85 0/36 0/56 0/56 0/51 0/66
 IR (95 % 
CI)
0 (0, 20.4) 0 (0, 40.4) 0 (0, 16.6) 0 (0, 54.1) 0 (0, 39.1) 0 (0, 30.9) 0 (38.2) 0 (0, 36.5)
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by a trial protocol. EMRs provide longitudinal data allow-
ing for better capture of events compared to reliance on indi-
vidual spontaneous adverse event reports. The study period 
duration of clinical trials is generally short compared to the 
present study with more extensive follow-up time for observ-
ing LC elevations. This study allows for comparison of LC 
elevations among a large number of patients with the same 
indication across different comparator drugs and multiple 
healthcare databases with diverse patient populations. The 
chart review and adjudication process by a panel of three 
physicians allowed for careful assessment of suspected DILI 
events in the VA population; this approach represents a gold 
standard of outcome ascertainment in retrospective studies.
Current post-marketing surveillance of pazopanib and 
other anti-VEGF drugs in RCC patients showed a relatively 
low frequency of serious liver events for approximately 
4 years of data collection. More data are needed to esti-
mate the rates of DILI or liver failure in pazopanib users. 
Understanding the incidence of severe liver injuries in RCC 
patients newly using pazopanib and other marketed anti-
VEGF agents in real-world clinical practice helps inform 
patients’ hepatic safety profile.
Acknowledgments This study was funded by GlaxoSmithKline 
(GSK).
Compliance with ethical standards 
Conflict of interest Sumitra Shantakumar and Jeanenne J. Nelson 
were employees and owned stock in GSK at the time that the study 
was designed and executed. Myrthe van Herk-Sukel is an employee of 
the PHARMO Institute. This independent research institute performs 
financially supported studies for government and related healthcare 
authorities and several pharmaceutical companies. Beth Nordstrom 
is an employee of Evidera, who received funding from GSK for this 
study. Susan A. Hall was an employee of New England Research Insti-
tutes, who received funding from GSK for this study.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, 
Hutson T, Harter P, Carpenter C, Pandite L, Kaplowitz N (2015) 
Characterisation of liver chemistry abnormalities associated with 
pazopanib monotherapy: a systematic review and meta-anal-
ysis of clinical trials in advanced cancer patients. Eur J Cancer 
51:1293–1302
 2. GlaxoSmithKline (2010) Votrient (pazopanib) tablets prescrib-
ing information. http://www.accessdata.fda.gov/drugsatfda_docs/
label/2014/022465s018lbl.pdf. Accessed 21 Oct 2014
 3. Kubota Y (2012) Tumor angiogenesis and anti-angiogenic ther-
apy. Keio J Med 61(2):47–56
 4. Iacovelli R, Palazzo A, Procopio G, Santoni M, Trenta P, De 
Benedetto A, Mezi S, Cortesi E (2014) Incidence and relative 
risk of hepatic toxicity in patients treated with antiangiogenic 
tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 
77(6):929–938
 5. Kapadia S, Hapani S, Choueiri TK, Wu S (2013) Risk of liver 
toxicity with the angiogenesis inhibitor pazopanib in cancer 
patients. Acta Oncol 52(6):1202–1212
 6. Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, 
Dematteo RP, D’Angelica MI (2011) Randomized phase II trial 
of adjuvant hepatic arterial infusion and systemic chemotherapy 
with or without bevacizumab in patients with resected hepatic 
metastases from colorectal cancer. J Clin Oncol 29(7):884–889
 7. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, 
Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A 
randomized trial of bevacizumab, an anti-vascular endothelial 
growth factor antibody, for metastatic renal cancer. N Engl J 
Med 349(5):427–434
 8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski 
RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, 
Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thomp-
son JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall sur-
vival and updated results for sunitinib compared with interferon 
alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 
27(22):3584–3590
 9. Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, Xu Y, 
Wang Z, Qiu SJ, Fan J, Zhou J (2012) Sorafenib in treatment of 
patients with advanced hepatocellular carcinoma: a systematic 
review. Hepatobiliary Pancreat Dis Int 11(5):458–466
 10. Pfizer Laboratories (2011) Sutent (sunitinib) prescribing informa-
tion. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/ 
021938s13s17s18lbl.pdf. Accessed 13 July 2015
 11. Reuben A (2004) Hy’s law. Hepatology 39:574–578
 12. Temple R (2006) Hy’s law: predicting serious hepatotoxicity. 
Pharmacoepidemiol Drug Saf 15:241–243
